Genetic variation in CYP2A6 predicts neural reactivity to smoking cues as measured using fMRI

NeuroImage

Volumn 60, Issue 4, 2012, Pages 2136-2143

  Tang, Deborah W ^a,b   Hello, Brian ^a   Mroziewicz, Margaret ^c   Fellows, Lesley K ^a,b   Tyndale, Rachel F ^c   Dagher, Alain ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cue conditioning; CYP2A6; FMRI; Genetics; Imaging; Smoking

Indexed keywords

CYTOCHROME P450 2A6; NICOTINE;

ADULT; AMYGDALOID NUCLEUS; ANTERIOR CINGULATE; ARTICLE; BLOOD LEVEL; CIGARETTE SMOKING; CINGULATE GYRUS; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC VARIABILITY; GENOTYPE; HIPPOCAMPUS; HUMAN; HUMAN EXPERIMENT; INSULA; MALE; METABOLIC RATE; METABOLISM; NICOTINE BLOOD LEVEL; NICOTINE METABOLISM; NORMAL HUMAN; PHENOTYPE; POSTERIOR CINGULATE; PREDICTION; PREFRONTAL CORTEX; PRIORITY JOURNAL; STIMULUS RESPONSE; STRIATE CORTEX; THALAMUS;

ADOLESCENT; ADULT; ARYL HYDROCARBON HYDROXYLASES; CUES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; NICOTINE; PHENOTYPE; SMOKING; TOBACCO USE DISORDER; YOUNG ADULT;

EID: 84858741963     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2012.01.119     Document Type: Article

References (68)

1. Abrams D.B., Monti P.M., Carey K.B., Pinto R.P., Jacobus S.I. Reactivity to smoking cues and relapse: two studies of discriminant validity. Behav. Res. Ther. 1988, 26:225-233.
2. Balfour D.J., Wright A.E., Benwell M.E., Birrell C.E. The putative role of extra-synaptic mesolimbic dopamine in the neurobiology of nicotine dependence. Behav. Brain Res. 2000, 113:73-83.
3. Benowitz N.L., Lessov-Schlaggar C.N., Swan G.E., Jacob P. Female sex and oral contraceptive use accelerate nicotine metabolism. Clin. Pharmacol. Ther. 2006, 79:480-488.
4. Benowitz N.L., Swan G.E., Jacob P., Lessov-Schlaggar C.N., Tyndale R.F. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin. Pharmacol. Ther. 2006, 80:457-467.
5. Brody A.L., Mandelkern M.A., London E.D., Childress A.R., Lee G.S., Bota R.G., Ho M.L., Saxena S., Baxter L.R., Madsen D., Jarvik M.E. Brain metabolic changes during cigarette craving. Arch. Gen. Psychiatry 2002, 59:1162-1172.
6. Brody A.L., Mandelkern M.A., Olmstead R.E., Jou J., Tiongson E., Allen V., Scheibal D., London E.D., Monterosso J.R., Tiffany S.T., Korb A., Gan J.J., Cohen M.S. Neural substrates of resisting craving during cigarette cue exposure. Biol. Psychiatry 2007, 62:642-651.
7. Caggiula A.R., Donny E.C., White A.R., Chaudhri N., Booth S., Gharib M.A., Hoffman A., Perkins K.A., Sved A.F. Cue dependency of nicotine self-administration and smoking. Pharmacol. Biochem. Behav. 2001, 70:515-530.
8. Cardinal R.N., Parkinson J.A., Hall J., Everitt B.J. Emotion and motivation: the role of the amygdala, ventral striatum, and prefrontal cortex. Neurosci. Biobehav. Rev. 2002, 26:321-352.
9. Carpenter M.J., Upadhyaya H.P., LaRowe S.D., Saladin M.E., Brady K.T. Menstrual cycle phase effects on nicotine withdrawal and cigarette craving: a review. Nicotine Tob. Res. 2006, 8:627-638.
10. Carver C., White T. Behavioral inhibition, behavioral activation, and affective responses to impending reward and punishment: the BIS/BAS Scales. J. Pers. Soc. Psychol. 1994, 67:319-333.
11. Chiamulera C. Cue reactivity in nicotine and tobacco dependence: a "multiple-action" model of nicotine as a primary reinforcement and as an enhancer of the effects of smoking-associated stimuli. Brain Res. Rev. 2005, 48:74-97.
12. Collins D., Neelin P., Peters T., Evans A.C. Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. J. Comput. Assist. Tomogr. 1994, 18:192-205.
13. Corrigall W.A., Franklin K.B., Coen K.M., Clarke P.B. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology 1992, 107:285-289.
14. Dagher A., Tannenbaum B., Hayashi T., Pruessner J.C., McBride D. An acute psychosocial stress enhances the neural response to smoking cues. Brain Res. 2009, 1293:40-48.
15. Dalley J.W., Laane K., Theobald D.E., Armstrong H.C., Corlett P.R., Chudasama Y., Robbins T.W. Time-limited modulation of appetitive Pavlovian memory by D1 and NMDA receptors in the nucleus accumbens. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:6189-6194.
16. Dani J.A., Heinemann S. Molecular and cellular aspects of nicotine abuse. Neuron 1996, 16:905-908.
17. Dar R., Frenk H. Reevaluating the nicotine delivery kinetics hypothesis. Psychopharmacology 2007, 192:1-7.
18. David S.P., Munafo M.R., Johansen-Berg H., Smith S.M., Rogers R.D., Matthews P.M., Walton R.T. Ventral striatum/nucleus accumbens activation to smoking-related pictorial cues in smokers and nonsmokers: a functional magnetic resonance imaging study. Biol. Psychiatry 2005, 58:488-494.
19. David S.P., Munafo M.R., Johansen-Berg H., MacKillop J., Sweet L., Cohen R., Niaura R., Rogers R., Matthews P.M., Walton R.T. Effects of acute nicotine abstinence on cue-elicited ventral striatum/nucleus accumbens activation in female cigarette smokers: a functional magnetic resonance imaging study. Brain Imaging Behav. 2007, 1:43-57.
20. Dempsey D., Tutka P., Jacob P., Allen F., Schoedel K., Tyndale R.F., Benowitz N.L. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin. Pharmacol. Ther. 2004, 76:64-72.
21. Di Chiara G. A motivational learning hypothesis of the role of mesolimbic dopamine in compulsive drug use. J. Psychopharmacol. 1998, 12:54-67.
22. Droungas A., Ehrman R.N., Childress A.R., O'Brien C.P. Effect of smoking cues and cigarette availability on craving and smoking behavior. Addict. Behav. 1995, 20:657-673.
23. Due D.L., Huettel S.A., Hall W.G. Activation in mesolimbic and visuospatial neural circuits elicited by smoking cues: evidence from functional magnetic resonance imaging. Am. J. Psychiatry 2002, 159:954.
24. Franklin T.R., Wang Z., Wang J., Sciortino N., Harper D., Li Y., Ehrman R., Kampman K., O'Brien C.P., Detre J.A., Childress A.R. Limbic activation to cigarette smoking cues independent of nicotine withdrawal: a perfusion fMRI study. Neuropsychopharmacology 2007, 32:2301-2309.
25. Franklin T.R., Lohoff F.W., Wang Z., Sciortino N., Harper D., Li Y., Jens W., Cruz J., Kampman K., Ehrman R., Berrettini W., Detre J.A., O'Brien C.P., Childress A.R. DAT genotype modulates brain and behavioral responses elicited by cigarette cues. Neuropsychopharmacology 2009, 34:717-728.
26. Franklin T., Wang Z., Suh J.J., Hazan R., Cruz J., Li Y., Goldman M., Detre J.A., O'Brien C.P., Childress A.R. Effects of varenicline on smoking cue-triggered neural and craving responses. Arch. Gen. Psychiatry 2011, 68:516-526.
27. Grenhoff J., Aston-Jones G., Svensson T.H. Nicotinic effects on the firing pattern of midbrain dopamine neurons. Acta Physiol. Scand. 1986, 128:351-358.
28. Heatherton T., Kozlowski L., Frecker R., Fagerstrom K. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Addiction 1991, 86:1119-1127.
29. Henningfield J., Heishman S. The addictive role of nicotine in tobacco use. Psychopharmacology 1995, 117:11-13.
30. Ho M.K., Mwenifumbo J.C., Al Koudsi N., Okuyemi K.S., Ahluwalia J.S., Benowitz N.L., Tyndale R.F. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin. Pharmacol. Ther. 2009, 85:635-643.
31. Janes A.C., Pizzagalli D.A., Richardt S., Bd Frederick, Chuzi S., Pachas G., Culhane M.A., Holmes A.J., Fava M., Evins A.E., Kaufman M.J. Brain reactivity to smoking cues prior to smoking cessation predicts ability to maintain tobacco abstinence. Biol. Psychiatry 2010, 67:722-729.
32. Kelley A.E., Schiltz C.A., Landry C.F. Neural systems recruited by drug- and food-related cues: studies of gene activation in corticolimbic regions. Physiol. Behav. 2005, 86:11-14.
33. Koob G.F., Volkow N.D. Neurocircuitry of Addiction. Neuropsychopharmacology 2009, 35:217-238.
34. Kriegeskorte N., Simmons W.K., Bellgowan P.S.F., Baker C.I. Circular analysis in systems neuroscience: the dangers of double dipping. Nat. Neurosci. 2009, 12:535-540.
35. Le Foll B., Goldberg S.R. Control of the reinforcing effects of nicotine by associated environmental stimuli in animals and humans. Trends Pharmacol. Sci. 2005, 26:287-293.
36. Lee J.-H., Lim Y., Wiederhold B., Graham S. A functional magnetic resonance imaging (fMRI) study of cue-induced smoking craving in virtual environments. Appl. Psychophysiol. Biofeedback 2005, 30:195-204.
37. Lerman C., Tyndale R., Patterson F., Wileyto E.P., Shields P.G., Pinto A., Benowitz N. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin. Pharmacol. Ther. 2006, 79:600-608.
38. Lerman C., Jepson C., Wileyto E.P., Patterson F., Schnoll R., Mroziewicz M., Benowitz N., Tyndale R.F. Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy. Clin. Pharmacol. Ther. 2010, 87:553-557.
39. Levin E.D., Simon B.B. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology 1998, 138:217-230.
40. McBride D., Barrett S.P., Kelly J.T., Aw A., Dagher A. Effects of expectancy and abstinence on the neural response to smoking cues in cigarette smokers: an fMRI study. Neuropsychopharmacology 2006, 31:2728-2738.
41. McClernon F., Hutchison K., Rose J., Kozink R. DRD4 VNTR polymorphism is associated with transient fMRI-BOLD responses to smoking cues. Psychopharmacology 2007, 194:433-441.
42. McClernon F.J., Kozink R.V., Rose J.E. Individual differences in nicotine dependence, withdrawal symptoms, and sex predict transient fMRI-BOLD responses to smoking cues. Neuropsychopharmacology 2008, 33:2148-2157.
43. McClernon F., Kozink R., Lutz A., Rose J. 24-h smoking abstinence potentiates fMRI-BOLD activation to smoking cues in cerebral cortex and dorsal striatum. Psychopharmacology 2009, 204:25-35.
44. Messina E.S., Tyndale R.F., Sellers E.M. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J. Pharmacol. Exp. Ther. 1997, 282:1608-1614.
45. Mwenifumbo J.C., Myers M.G., Wall T.L., Lin S.-K., Sellers E.M., Tyndale R.F. Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method. Pharmacogenet. Genomics 2005, 15:189-192.
46. Mwenifumbo J.C., Sellers E.M., Tyndale R.F. Nicotine metabolism and CYP2A6 activity in a population of black African descent: impact of gender and light smoking. Drug Alcohol Depend. 2007, 89:24-33.
47. Patterson F., Schnoll R.A., Wileyto E.P., Pinto A., Epstein L.H., Shields P.G., Hawk L.W., Tyndale R.F., Benowitz N., Lerman C. Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin. Pharmacol. Ther. 2008, 84:320-325.
48. Payne T.J., Smith P.O., Adams S.G., Diefenbach L. Pretreatment cue reactivity predicts end-of-treatment smoking. Addict. Behav. 2006, 31:702-710.
49. Picciotto M.R., Brunzell D.H., Caldarone B.J. Effect of nicotine and nicotinic receptors on anxiety and depression. Neuroreport 2002, 13:1097-1106.
50. Pihl R., Peterson J. Alcoholism: the role of different motivational systems. J. Psychiatry Neurosci. 1995, 20:372-396.
51. Poldrack R.A. Region of interest analysis for fMRI. Soc. Cogn. Affect. Neurosci. 2007, 2:67-70.
52. Poline J.B., Worsley K.J., Evans A.C., Friston K.J. Combining spatial extent and peak intensity to test for activations in functional imaging. Neuroimage 1997, 5:83-96.
53. Robinson T.E., Berridge K.C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res. Brain Res. Rev. 1993, 18:247-291.
54. Robinson T.E., Berridge K.C. Addiction. Annu. Rev. Psychol. 2003, 54:25-53.
55. Saxe R., Brett M., Kanwisher N. Divide and conquer: a defense of functional localizers. Neuroimage 2006, 30:1088-1096.
56. Sayette M.A., Shiffman S., Tiffany S.T., Niaura R.S., Martin C.S., Schadel W.G. The measurement of drug craving. Addiction 2000, 95:189-210.
57. Schiffman S., Gwaltney C., Balabanis M., Liu K., Paty J.A., Kassel J., Hickcox M., Gnys M. Immediate antecedents of cigarette smoking: an analysis from ecological momentary assessment. J. Abnorm. Psychol. 2002, 111:531-545.
58. Schoedel K.A., Hoffmann E.B., Rao Y., Sellers E.M., Tyndale R.F. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenet. Genomics 2004, 14:615-626.
59. Schultz W. Behavioral theories and the neurophysiology of reward. Annu. Rev. Psychol. 2005, 57:87-115.
60. Schultz W., Dayan P., Montague P.R. A neural substrate of prediction and reward. Science 1997, 275:1593-1599.
61. Spielberger C.D. Manual for the State-Trait Anxiety Inventory: STAI (Form Y) 1983, Consulting Psychologists Press.
62. Tang J., Dani J.A. Dopamine enables in vivo synaptic plasticity associated with the addictive drug nicotine. Neuron 2009, 63:673-682.
63. Tiffany S.T., Drobes D.J. The development and initial validation of a questionnaire on smoking urges. Br. J. Addict. 1991, 86:1467-1476.
64. Wassenaar C.A., Dong Q., Wei Q., Amos C.I., Spitz M.R., Tyndale R.F. Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. J. Natl. Cancer Inst. 2011, 103:1342-1346.
65. Wilson S.J., Sayette M.A., Fiez J.A. Prefrontal responses to drug cues: a neurocognitive analysis. Nat. Neurosci. 2004, 7:211-214.
66. Wilson S.J., Sayette M.A., Delgado M.R., Fiez J.A. Instructed smoking expectancy modulates cue-elicited neural activity: a preliminary study. Nicotine Tob. Res. 2005, 7:637-645.
67. Worsley K.J., Liao C.H., Aston J., Petre V., Duncan G.H., Morales F., Evans A.C. A general statistical analysis for fMRI data. Neuroimage 2002, 15:1-15.
68. Zhang T., Zhang L., Liang Y., Siapas A.G., Zhou F.M., Dani J.A. Dopamine signaling differences in the nucleus accumbens and dorsal striatum exploited by nicotine. J. Neurosci. 2009, 29:4035-4043.